Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
This has pushed the research studies to evaluate immunotherapy in combination with other cancer targeting approaches including chemotherapy, radiotherapy, targeted drugs, and other immunotherapeutic approaches. The combination therapy aims to combine two or more drugs which have synergistic mechanism of action in targeting the disease. In comparison to monotherapy, combinational therapy aims to have more enhanced and additive effect in the targeting of cancer cells. Further, it also has the potential to overcome the drug resistance and enhance the overall survival rate in cancer patients. The conferred advantages associated with combinational therapies have drawn the interest of several pharmaceutical giants to invest in this segment.
Currently, several drugs such as Opdivo, Yervoy, Bevacizumab, and others have gained approval as combinational immunotherapy for the management of cancer cells In 2022, US FDA has granted approval to the fixed dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The novel combination has shown manageable safety with no new or unexpected safety signals. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb.
In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. The manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge, and expand business. For instance, Gilead Sciences entered into two clinical trial collaboration and supply agreements with Merck to evaluate the combination of Trodelvy and Keytruda in first-line metastatic non-small cell lung cancer. Additionally, the companies recently established an agreement whereby Gilead will sponsor a phase-II signal seeking study evaluating combinations that include pembrolizumab in first line non-small cell lung cancer.
Triple combinational therapy is also gaining considerable momentum in the market. However, it is mainly confined to initial stages of clinical development. For instance, Zenith Pharmaceutical in collaboration with Bristol Myers Squibb is conducting clinical trial which is evaluating triple combination of ZEN-3694 (BET inhibitor), Opdio, and Yervoy. The trial will be conducted by NCI funded investigators and will evaluate the safety and activity of this combination in patients with solid tumors that have become resistant to other therapies. Apart from this, a triple combinational therapy of PD-1/PD-L1, BRAF, and MEK inhibitor is also ongoing in multiple myeloma patients.
As per our report findings, the global combinational immunotherapy market is expected to surpass US$ 15 Billion by 2028. This is mainly attributed to rising geriatric population and surge in prevalence of various cancers. This possesses high medical needs for the development of targeted therapies in its management. In addition, rising investments by pharmaceutical companies due to promising response of combinational immunotherapy is also driving the growth of market. The major players in the global combinational immunotherapy market include Amgen, Roche, Macrogenics, Mylan, Seagen, AstraZeneca, Gilead Sciences, GlaxoSmithKline, and others.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
- Combination Cancer Immunotherapy Market By 15 Different Cancers
- Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
This has pushed the research studies to evaluate immunotherapy in combination with other cancer targeting approaches including chemotherapy, radiotherapy, targeted drugs, and other immunotherapeutic approaches. The combination therapy aims to combine two or more drugs which have synergistic mechanism of action in targeting the disease. In comparison to monotherapy, combinational therapy aims to have more enhanced and additive effect in the targeting of cancer cells. Further, it also has the potential to overcome the drug resistance and enhance the overall survival rate in cancer patients. The conferred advantages associated with combinational therapies have drawn the interest of several pharmaceutical giants to invest in this segment.
Currently, several drugs such as Opdivo, Yervoy, Bevacizumab, and others have gained approval as combinational immunotherapy for the management of cancer cells In 2022, US FDA has granted approval to the fixed dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The novel combination has shown manageable safety with no new or unexpected safety signals. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb.
In last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. The manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge, and expand business. For instance, Gilead Sciences entered into two clinical trial collaboration and supply agreements with Merck to evaluate the combination of Trodelvy and Keytruda in first-line metastatic non-small cell lung cancer. Additionally, the companies recently established an agreement whereby Gilead will sponsor a phase-II signal seeking study evaluating combinations that include pembrolizumab in first line non-small cell lung cancer.
Triple combinational therapy is also gaining considerable momentum in the market. However, it is mainly confined to initial stages of clinical development. For instance, Zenith Pharmaceutical in collaboration with Bristol Myers Squibb is conducting clinical trial which is evaluating triple combination of ZEN-3694 (BET inhibitor), Opdio, and Yervoy. The trial will be conducted by NCI funded investigators and will evaluate the safety and activity of this combination in patients with solid tumors that have become resistant to other therapies. Apart from this, a triple combinational therapy of PD-1/PD-L1, BRAF, and MEK inhibitor is also ongoing in multiple myeloma patients.
As per our report findings, the global combinational immunotherapy market is expected to surpass US$ 15 Billion by 2028. This is mainly attributed to rising geriatric population and surge in prevalence of various cancers. This possesses high medical needs for the development of targeted therapies in its management. In addition, rising investments by pharmaceutical companies due to promising response of combinational immunotherapy is also driving the growth of market. The major players in the global combinational immunotherapy market include Amgen, Roche, Macrogenics, Mylan, Seagen, AstraZeneca, Gilead Sciences, GlaxoSmithKline, and others.
1. COMBINATION CANCER IMMUNOTHERAPY – NEW ERA IN CANCER RESEARCH
2. NEED FOR COMBINATION CANCER IMMUNOTHERAPY
3. CLINICALLY & COMMERCIALLY APPROVED COMBINATION CANCER IMMUNOTHERAPY
4. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS
4.1 Current Market Scenario
4.2 Future Market Opportunity
5. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS BY INDICATION
5.1 Breast Cancer
5.2 Kidney Cancer
5.3 Lung Cancer
5.4 Liver Cancer
5.5 Gastric Cancer
5.6 Lymphoma
5.7 Prostate Cancer
5.8 Melanoma
5.9 Colorectal Cancer
5.10 Leukemia
5.11 Cervical Cancer
5.12 Pancreatic Cancer
5.13 Ovarian Cancer
5.14 Head & Neck Cancer
5.15 Multiple Myeloma
6. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS BY REGION
6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 Australia
6.6 South Korea
6.7 Canada
6.8 UK
7. APPROVED IMMUNE CHECKPOINT INHIBITOR IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
7.1 Patent, Price & Dosage Analysis
7.2 Global & Regional Sales Insights
8. APPROVED ANTIBODY DRUG CONJUGATE IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
8.1 Patent, Price & Dosage Analysis
8.2 Global & Regional Sales Insights
9. APPROVED MONOCLONAL ANTIBODIES IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
9.1 Patent, Price & Dosage Analysis
9.2 Global & Regional Sales Insights
10. COMBINATION CANCER IMMUNOTHERAPY CLINICAL TRIALS OVERVIEW
10.1 By Company
10.2 By Country
10.3 By Patient Segment/Disease Stage
10.4 By Phase
11. COMBINATION CANCER IMMUNOTHERAPY CLINICAL TRIALS & PATENT INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered
12. MARKETED COMBINATION CANCER IMMUNOTHERAPY CLINICAL & PATENT INSIGHT BY COMPANY, COUNTRY, & INDICATION
13. COMBINATION STRATEGIES TO ENHANCE IMMUNE CHECKPOINT INHIBITORS EFFICACY
13.1 In Combination with Other Immune Checkpoint Blockade:
13.2 Ongoing Clinical Trials of ICI with Conventional Therapies; Chemotherapy & Radiation
13.3 ICI Trials with Other Targeted Therapies
13.4 Recent Trends in Market: Partnerships, Collaboration, & Investments
14. COMBINATION OF THERAPEUTIC ANTIBODIES IN CLINICAL ONCOLOGY
14.1 Combination Trials of Monoclonal Antibodies
14.2 Clinical Trials of Bispecific Antibody Combination Therapy
14.3 Pharmaceutical Investments Boosting Market
15. ENGAGING CANCER VACCINES IN COMBINATION THERAPY
15.1 Preclinical Studies Evaluating Vaccines in Combination Therapy
15.2 Clinical Trials Evaluating Cancer Vaccines in Combination Approach
15.3 Ongoing Research Agreement & Collaboration
16. ANTIBODY DRUG CONJUGATE IN COMBINATION THERAPY
16.1 Ongoing Clinical Investigations
16.2 Pharmaceutical Collaborations & Supply Agreements
17. COMBINATION THERAPY WITH CAR T CELL THERAPY
17.1 Preclinical Studies Combining CAR T cell Therapy
17.2 Clinical Trials Evaluating Combination Therapies with CAR T Cells
17.3 Ongoing Research & Development Activities
18. ONCOLYTIC VIRUS COMBINATION THERAPY
18.1 OV Combination Immunotherapy
18.2 Oncolytic Virus in Combination with Other Regimens
18.3 Recent Trends in Market: Partnerships, Collaboration, & Investments
19. COMPETITIVE LANDSCAPE
19.1 AbbVie
19.2 Agenus
19.3 Akeso Pharmaceutical
19.4 Amgen
19.5 Arbutus Biopharma
19.6 AstraZeneca
19.7 AUM Bioscience
19.8 BeiGene
19.9 BioNTech
19.10 Bristol Myers Squibb
19.11 Candel Therapeutics
19.12 Eli Lilly
19.13 Elicio Therapeutics
19.14 Fate Therapeutics
19.15 GlaxoSmithKline
19.16 Harpoon Therapeutics
19.17 Immutep
19.18 Imugene
19.19 Intensity Therapeutics
19.20 Janssen Pharmaceuticals
19.21 Merck
19.22 MorphoSys
19.23 Novocure
19.24 Novartis
19.25 Nykode Therapeutics
19.26 Ono Pharmaceutical
19.27 Oxford Biotherapeutics
19.28 Pfizer
19.29 Regeneron
19.30 Roche
19.31 Sanofi
19.32 Seagen
19.33 Shanghai Junshi Biosciences
19.34 Takeda Pharmaceuticals
19.35 Qurient
2. NEED FOR COMBINATION CANCER IMMUNOTHERAPY
3. CLINICALLY & COMMERCIALLY APPROVED COMBINATION CANCER IMMUNOTHERAPY
4. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS
4.1 Current Market Scenario
4.2 Future Market Opportunity
5. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS BY INDICATION
5.1 Breast Cancer
5.2 Kidney Cancer
5.3 Lung Cancer
5.4 Liver Cancer
5.5 Gastric Cancer
5.6 Lymphoma
5.7 Prostate Cancer
5.8 Melanoma
5.9 Colorectal Cancer
5.10 Leukemia
5.11 Cervical Cancer
5.12 Pancreatic Cancer
5.13 Ovarian Cancer
5.14 Head & Neck Cancer
5.15 Multiple Myeloma
6. GLOBAL COMBINATION CANCER IMMUNOTHERAPY MARKET SIZE & TREND ANALYSIS BY REGION
6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 Australia
6.6 South Korea
6.7 Canada
6.8 UK
7. APPROVED IMMUNE CHECKPOINT INHIBITOR IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
7.1 Patent, Price & Dosage Analysis
7.2 Global & Regional Sales Insights
8. APPROVED ANTIBODY DRUG CONJUGATE IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
8.1 Patent, Price & Dosage Analysis
8.2 Global & Regional Sales Insights
9. APPROVED MONOCLONAL ANTIBODIES IN COMBINATION CANCER IMMUNOTHERAPY – CLINICAL & COMMERCIAL INSIGHTS
9.1 Patent, Price & Dosage Analysis
9.2 Global & Regional Sales Insights
10. COMBINATION CANCER IMMUNOTHERAPY CLINICAL TRIALS OVERVIEW
10.1 By Company
10.2 By Country
10.3 By Patient Segment/Disease Stage
10.4 By Phase
11. COMBINATION CANCER IMMUNOTHERAPY CLINICAL TRIALS & PATENT INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered
12. MARKETED COMBINATION CANCER IMMUNOTHERAPY CLINICAL & PATENT INSIGHT BY COMPANY, COUNTRY, & INDICATION
13. COMBINATION STRATEGIES TO ENHANCE IMMUNE CHECKPOINT INHIBITORS EFFICACY
13.1 In Combination with Other Immune Checkpoint Blockade:
13.2 Ongoing Clinical Trials of ICI with Conventional Therapies; Chemotherapy & Radiation
13.3 ICI Trials with Other Targeted Therapies
13.4 Recent Trends in Market: Partnerships, Collaboration, & Investments
14. COMBINATION OF THERAPEUTIC ANTIBODIES IN CLINICAL ONCOLOGY
14.1 Combination Trials of Monoclonal Antibodies
14.2 Clinical Trials of Bispecific Antibody Combination Therapy
14.3 Pharmaceutical Investments Boosting Market
15. ENGAGING CANCER VACCINES IN COMBINATION THERAPY
15.1 Preclinical Studies Evaluating Vaccines in Combination Therapy
15.2 Clinical Trials Evaluating Cancer Vaccines in Combination Approach
15.3 Ongoing Research Agreement & Collaboration
16. ANTIBODY DRUG CONJUGATE IN COMBINATION THERAPY
16.1 Ongoing Clinical Investigations
16.2 Pharmaceutical Collaborations & Supply Agreements
17. COMBINATION THERAPY WITH CAR T CELL THERAPY
17.1 Preclinical Studies Combining CAR T cell Therapy
17.2 Clinical Trials Evaluating Combination Therapies with CAR T Cells
17.3 Ongoing Research & Development Activities
18. ONCOLYTIC VIRUS COMBINATION THERAPY
18.1 OV Combination Immunotherapy
18.2 Oncolytic Virus in Combination with Other Regimens
18.3 Recent Trends in Market: Partnerships, Collaboration, & Investments
19. COMPETITIVE LANDSCAPE
19.1 AbbVie
19.2 Agenus
19.3 Akeso Pharmaceutical
19.4 Amgen
19.5 Arbutus Biopharma
19.6 AstraZeneca
19.7 AUM Bioscience
19.8 BeiGene
19.9 BioNTech
19.10 Bristol Myers Squibb
19.11 Candel Therapeutics
19.12 Eli Lilly
19.13 Elicio Therapeutics
19.14 Fate Therapeutics
19.15 GlaxoSmithKline
19.16 Harpoon Therapeutics
19.17 Immutep
19.18 Imugene
19.19 Intensity Therapeutics
19.20 Janssen Pharmaceuticals
19.21 Merck
19.22 MorphoSys
19.23 Novocure
19.24 Novartis
19.25 Nykode Therapeutics
19.26 Ono Pharmaceutical
19.27 Oxford Biotherapeutics
19.28 Pfizer
19.29 Regeneron
19.30 Roche
19.31 Sanofi
19.32 Seagen
19.33 Shanghai Junshi Biosciences
19.34 Takeda Pharmaceuticals
19.35 Qurient
LIST OF FIGURES
Figure 1-1: Currently Available Immunotherapeutic Approaches
Figure 1-2: Basis of Combination Immunotherapy
Figure 4-1: Global – Combination Cancer Immunotherapy Market Size (US$ Billion), 2020 & 2021
Figure 4-2: Global – Cancer Combination Immunotherapy Market by Indication (US$ Million), 2021
Figure 4-3: Global – Cancer Combination Immunotherapy Market by Indication (%), 2021
Figure 4-4: Global – Cancer Combination Immunotherapy Market by Region (US$ Million), 2021
Figure 4-5: Global – Cancer Combination Immunotherapy Market by Region (%), 2021
Figure 4-6: Global – Combination Cancer Immunotherapy Market Size (US$ Billion), 2022 - 2028
Figure 5-1: Global – Breast Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-2: Global – Breast Combination Cancer Immunotherapy Market Size (US$ Billion), 2020 & 2021
Figure 5-3: Global – Breast Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-4: Global – Kidney Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-5: Global – Kidney Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-6: Global – Lung Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-7: Global – Lung Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-8: Global – Liver Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-9: Global – Liver Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-10: Global – Gastric Combination Cancer Immunotherapy Market Size (US$ Million), 2021 - 2028
Figure 5-11: Global – Lymphoma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-12: Global – Lymphoma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-13: Global – Prostate Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-14: Global – Melanoma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-15: Global – Melanoma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-16: Global – Colorectal Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-17: Global – Colorectal Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-18: Global – Leukemia Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-19: Global – Leukemia Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-20: Global – Cervical Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-21: Global – Cervical Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-22: Global – Pancreatic Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-23: Global – Pancreatic Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-24: Global – Ovarian Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-25: Global – Ovarian Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-26: Global – Head & Neck Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-27: Global – Head & Neck Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-28: Global – Multiple Myeloma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-29: Global – Multiple Myeloma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-1: US – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-2: US vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-3: US – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-4: Europe – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-5: Europe vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-6: Europe vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-7: Europe – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-8: China – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-9: China vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-10: China vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-11: China – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-12: Japan – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-13: Japan vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-14: Japan vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-15: Japan – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-16: Australia – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-17: Australia vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-18: Australia vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-19: Australia – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-20: South Korea – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-21: South Korea – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-22: Canada – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-23: Canada vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-24: Canada vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-25: Canada – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-26: UK – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-27: UK vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-28: UK vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-29: UK – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 7-1: Keytruda – Approval Year by Region
Figure 7-2: Keytruda Combination – FDA Approval Year by Indication
Figure 7-3: Keytruda Combination – EMA Approval Year by Indication
Figure 7-4: Keytruda – Patent Expiration Year by Region
Figure 7-5: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), June’2022
Figure 7-6: UK - Price for 4ml & Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), June’2022
Figure 7-7: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks),
Figure 7-8: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), June’2022
Figure 7-9: Opdivo – Approval Year by Region
Figure 7-10: Opdivo Combination – FDA Approval by Indication
Figure 7-11: Opdivo - Patent Expiration Year by Region
Figure 7-12: US - Price for 4ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-13: US - Price for 10 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-14: US - Price for 12 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-15: US - Price for 24 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-16: UK - Price for 4 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-17: UK - Price for 10ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-18: UK - Price for 24ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-19: Opdivo Combination Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June’2022
Figure 7-20: Yervoy Combination – FDA Approval Year by Region
Figure 7-21: Yervoy – Approval Year by Region
Figure 7-22: Yervoy – US & Europe Exclusivity Expiration Year
Figure 7-23: US - Price for 10ml Supply & Price Per ml of Yervoy 5mg/ml Intravenous Injection (US$), June’2022
Figure 7-24: US – Price for 40ml Supply & Price Per ml 5mg/ml Yervoy Intravenous Injection (US$), June’2022
Figure 7-25: UK - Price for 10ml & Price Per ml of Yervoy 50mg Intravenous Injection (GBP/US$), June’2022
Figure 7-26: UK - Price for 40ml & Price Per ml of Yervoy 200mg Intravenous Injection (GBP/US$), June’2022
Figure 7-27: Yervoy - Single Treatment Cycle & Full Treatment Average Cost for NSCLC (US$), June’2022
Figure 7-28: Yervoy & Opdivo Combination - Single Treatment Cycle & Full Treatment Average Cost for NSCLC (US$), June’2022
Figure 7-29: Imfinzi – Approval Year by Region
Figure 7-30: Imfinzi – FDA Approval & Patent Expiration Year
Figure 7-31: US– Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (US$), June’2022
Figure 7-32: US – Price for a Supply of 10 ml & Price Per ml of Imfinzi Solution for Injection (US$), June’2022
Figure 7-33: UK– Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (GBP/US$), June’2022
Figure 7-34: UK– Price for a Supply of 10ml & Price Per ml of Imfinzi Solution for Injection (GBP/US$), June’2022
Figure 7-35: Imfinzi Combination Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June’2022
Figure 7-36: Tecentriq – Approval Year by Region
Figure 7-37: Tecentriq Combination – FDA Approval Year by Indication
Figure 7-38: US- Price for 14ml Supply & Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), June’2022
Figure 7-39: US - Price for 20ml Supply & Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), June’2022
Figure 7-40: UK– Price for a Supply of 20ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), June’2022
Figure 7-41: UK– Price for a Supply of 14ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), June’2022
Figure 7-42: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), June’2022
Figure 7-43: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), June’2022
Figure 7-44: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), June’2022
Figure 7-45: Tuoyi – NMPA Approval by Indication
Figure 7-46: China– Price for a Supply of 2ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-47: China– Price for a Supply of 2.5ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-48: China– Price for a Supply of 6ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-49: Tislelizumab – NMPA Approval by Indication
Figure 7-50: US – Opdualag FDA Orphan Designation & Approval Year
Figure 7-51: US - Price for 20ml Supply & Price Per ml of Opdualag Intravenous Injection (US$), June’2022
Figure 7-52: Global - Keytruda Sales (US$ Million), Q1’2021 & Q1’2022
Figure 7-53: Global - Keytruda Sales Value (US$ Billion), 2018 - 2021
Figure 7-54: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 7-55: Global – Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 7-56: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022
Figure 7-57: Global - Opdivo Sales Value by Region (%), Q1’2022
Figure 7-58: Global - Opdivo Sales Value (US$ Million), 2018 - 2021
Figure 7-59: US - Opdivo Sales Value (US$ Million), 2018 - 2021
Figure 7-60: Global – Opdivo Sales Value by Region (US$ Million), 2021
Figure 7-61: Global - Opdivo Sales Value by Region (%), 2021
Figure 7-62: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-63: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-64: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-65: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-66: Global - Yervoy Sales Value by Region (US$ Million), Q1’2022
Figure 7-67: Global – Yervoy Sales Value by Region (%), Q1’2022
Figure 7-68: Global - Yervoy Sales Value (US$ Million), 2018 - 2021
Figure 7-69: US - Yervoy Sales Value (US$ Million), 2018 - 2021
Figure 7-70: Yervoy - Sales Value by Region (US$ Million), 2021
Figure 7-71: Yervoy - Sales Value by Region (US$ Million), 2021
Figure 7-72: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-73: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-74: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-75: US - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-76: Imfinzi – Sales Value by Region (US$ Million), Q1’2022
Figure 7-77: Imfinzi – Sales Value by Region (US$ Million), Q1’2022
Figure 7-78: Global - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-79: US - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-80: Europe - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-81: Imfinzi - Sales Value by Region (US$ Million), 2021
Figure 7-82: Imfinzi - Sales Value by Region (%), 2021
Figure 7-83: Global - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 7-84: US - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 7-85: Global - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 7-86: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 7-87: Tecentriq – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 7-88: Tecentriq – Sales Value by Region (%), Q1’2022
Figure 7-89: Global - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-90: US - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-91: Europe - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-92: Japan - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-93: ROW - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-94: Tecentriq - Sales Value by Region (US$/CHF Million), 2021
Figure 7-95: Tecentriq - Sales Value by Region (%), 2021
Figure 7-96: Global - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-97: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-98: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-1: Adcetris Combination - Approval Year by Region
Figure 8-2: Adcetris Combination - Approval Year in Hodgkin Lymphoma by Region
Figure 8-3: Adcetris Combination - Approval Year in Large Cell Lymphoma by Region
Figure 8-4: Adcetris - Patent Expiration by Region
Figure 8-5: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), June’2022
Figure 8-6: Adcetris - Cost of Supply of Vial for Injection by Region (US$), June’2022
Figure 8-7: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 8-8: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), June’2022
Figure 8-9: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 8-10: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), June’2022
Figure 8-11: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), June’2022
Figure 8-12: Polivy Combination - Approval Year by Region
Figure 8-13: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), June’2022
Figure 8-14: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), June’2022
Figure 8-15: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 8-16: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of DLBCL (US$), June’2022
Figure 8-17: Global - Adcetris Sales (US$ Million), Q1’2021 & Q1’2022
Figure 8-18: Global - Adcetris Sales Value (US$ Million), 2018 - 2021
Figure 8-19: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 8-20: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 8-21: Polivy – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-22: Polivy – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-23: Global - Polivy Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-24: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-25: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-26: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-27: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 8-28: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-29: Polivy - Sales Value by Region (US$/CHF Million), 2021
Figure 8-30: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 8-31: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-32: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-33: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-34: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 8-35: Polivy - Sales Value by Region (%), 2020
Figure 8-36: Polivy – Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 9-1: Avastin – Approval Year by Region
Figure 9-2: Avastin Combination – FDA Approval Year by Indication
Figure 9-3: US– Price for a Supply of 10 & Price for Single 4ml Avastin Solution for Injection (US$), June’2022
Figure 9-4: US – Price for a Supply of 10 & Price for Single 16ml Avastin Solution for Injection (US$), June’2022
Figure 9-5: UK– Price for a Supply of 4ml & Price Per ml of Avastin Solution for Injection (GBP/US$), June’2022
Figure 9-6: UK– Price for a Supply of 16ml & Price Per ml of Avastin Solution for Injection (GBP/US$), June’2022
Figure 9-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Cervical Cancer (US$), June’2022
Figure 9-8: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combination & Monotherapy (Weeks)
Figure 9-9: Mvasi – Approval Year by Region
Figure 9-10: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-11: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), June’2022
Figure 9-12: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), June’2022
Figure 9-13: US– Price for a Supply of 4ml & Price Per ml of Zirabev Solution for Injection (US$), June’2022
Figure 9-14: US– Price for a Supply of 16ml & Price Per ml of Zirabev Solution for Injection (US$), June’2022
Figure 9-15: UK– Price for a Supply of 16ml, 4ml & Price Per ml of Zirabev Solution for Injection (GBP/US$), June’2022
Figure 9-16: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC (US$), June’2022
Figure 9-17: UK– Price for a Supply of 4ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), June’2022
Figure 9-18: UK– Price for a Supply of 16ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), June’2022
Figure 9-19: Arzerra – FDA Approval Year by Therapy
Figure 9-20: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), June’2022
Figure 9-21: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-22: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg)
Figure 9-23: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), June’2022
Figure 9-24: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg)
Figure 9-25: Arzerra – Treatment Duration for Refractory CLL (Weeks)
Figure 9-26: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), June’2022
Figure 9-27: Gazyva – FDA Approval Year by Therapy
Figure 9-28: US – Price for 40ml Supply & Price Per ml of Gazyva Intravenous Solution (US$), June’2022
Figure 9-29: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)
Figure 9-30: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week)
Figure 9-31: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), June’2022
Figure 9-32: US– Price for 5ml & Price Per ml of Herceptin Hylecta Subcutaneous Solution for Injection (US$), June’2022
Figure 9-33: Herceptin Hylecta – Duration of Single Treatment Cycle & Full Treatment (week)
Figure 9-34: Herceptin Hylecta – Cost of Single Treatment Cycle & Full Treatment (US$), June’2022
Figure 9-35: US– Price for various Supplies of Phesgo Subcutaneous Solution for Injection (US$), June’2022
Figure 9-36: UK– Price for a Supply of 16ml & 10ml of Phesgo Solution for Injection (GBP/US$), June’2022
Figure 9-37: Phesgo – Duration of Treatment by Type (Cycles)
Figure 9-38: Sarclisa – FDA Approval by Type
Figure 9-39: Sarclisa – FDA Approval & Patent Expiration Year
Figure 9-40: US – Price for 5 ml Supply & Price Per ml of Sarclisa 20mg/ml Intravenous Solution (US$), June’2022
Figure 9-41: US– Price for 25 ml Supply & Price Per ml of 20mg/ml Sarclisa Intravenous Solution (US$), June’2022
Figure 9-42: UK– Price for a Supply of 25ml & 5ml of Phesgo Solution for Injection (GBP/US$), June’2022
Figure 9-43: Sarclisa – Number of Dose Required in Initial & Subsequent Treatment Cycles (Weeks)
Figure 9-44: Herceptin Combination – FDA Approval Year by Cancer Type
Figure 9-45: Herceptin –Approval Year by Region
Figure 9-46: US– Price for a Supply of 10 & Price for Single Herceptin 150mg Powder for Injection (US$), June’2022
Figure 9-47: UK– Price for Single Herceptin 150mg Powder for Injection (GBP/US$), June’2022
Figure 9-48: Herceptin Combination – Initial & Maintenance Dose for Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
Figure 9-49: Ogivri –Approval Year by Region
Figure 9-50: Ogivri – Price for 150mg & 420mg Powder for Injection (US$), June’2022
Figure 9-51: Ogivri – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-52: Ogivri – Average Cost of Initial Week, Maintenance Week & Annual (US$), June’2022
Figure 9-53: Herzuma –Approval Year by Region
Figure 9-54: US– Price for 150mg & 420mg Herzuma Powder for Injection (US$), June’2022
Figure 9-55: UK– Price for 150mg & 420mg Herzuma Powder for Injection (GBP/US$), June’2022
Figure 9-56: Herzuma – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-57: Herzuma – Average Cost of Initial Week, Maintenance Week & Annual (US$), June’2022
Figure 9-58: Trazimera –Approval Year by Region
Figure 9-59: US– Price for 150mg & 420mg Trazimera Powder for Injection (US$), June’2022
Figure 9-60: UK– Price for 150mg & 420mg Trazimera Powder for Injection (GBP/US$), June’2022
Figure 9-61: Trazimera – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-62: Trazimera – Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), June’2022
Figure 9-63: Kanjinti –Approval Year by Region
Figure 9-64: US – Price for 150mg & 420mg Powder for Injection (US$), June’2022
Figure 9-65: UK– Price for 150mg & 420mg Kanjinti Powder for Injection (GBP/US$), June’2022
Figure 9-66: Kanjinti – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-67: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), June’2022
Figure 9-68: UK– Price for Single Zercepac 150mg Powder for Injection (GBP/US$), June’2022
Figure 9-69: Zercepac – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-70: Zercepac – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), June’2022
Figure 9-71: Darzalex Faspro – FDA Approval & Patent Expiration Year
Figure 9-72: US – Price for 15 ml Supply & Price Per ml of Darzalex Faspro Subcutaneous Solution (US$), June’2022
Figure 9-73: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 9-74: Tafasitamab Combination – Approval Year by Region
Figure 9-75: Monjuvi – Number of Dose per Treatment Cycle by Phase
Figure 9-76: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 9-77: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), June’2022
Figure 9-78: Rituxan Combination – FDA Approval Year by Indication
Figure 9-79: MabThera – Approval Year by Region
Figure 9-80: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US$), June’2022
Figure 9-81: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US$), June’2022
Figure 9-82: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US$), June’2022
Figure 9-83: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), June’2022
Figure 9-84: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), June’2022
Figure 9-85: Rituxan Combination – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022
Figure 9-86: Rituxan Combination – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June’2022
Figure 9-87: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), June’2022
Figure 9-88: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), June’2022
Figure 9-89: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-90: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US$), June’2022
Figure 9-91: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022
Figure 9-92: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June’2022
Figure 9-93: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-94: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-95: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), June’2022
Figure 9-96: Ruxience – Approval Year by Region
Figure 9-97: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-98: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-99: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-100: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-101: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), June’2022
Figure 9-102: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), June’2022
Figure 9-103: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), June’2022
Figure 9-104: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 9-105: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US$), June’2022
Figure 9-106: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (weeks)
Figure 9-107: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US$), June’2022
Figure 9-108: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), June’2022
Figure 9-109: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 9-110: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), June’2022
Figure 9-111: Erbitux Combination - Approval Year by Cancer Type
Figure 9-112: US - Price for a Supply of 50 ml & Per unit Price of Erbitux Intravenous Solution (US$), June’2022
Figure 9-113: US - Price for a Supply of 100 ml & Per unit Price of Erbitux Intravenous Solution (US$), June’2022
Figure 9-114: UK – Cost of 100ml, 20ml & Per Unit Cost of Erbitux Solution (GBP/US$), June’2022
Figure 9-115: Cetuximab Combination – Initial & Maintenance Dose for Colorectal Cancer & Head and Neck Cancer (mg/ m2)
Figure 9-116: Cetuximab – Recommended Dose & Reduced Dose (mg/ m2)
Figure 9-117: Naxitamab – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), June’2022
Figure 9-118: Empliciti – FDA Approval by Therapy Type
Figure 9-119: Empliciti – Aooroval Year by Region
Figure 9-120: Empliciti – Patent Issue & Expiration Year
Figure 9-121: US – Price for 300mg & 400mg Supply of Empliciti Intravenous Powder for Injection (US$), June’2022
Figure 9-122: UK – Price for 300mg & 400mg Supply of Empliciti Intravenous Powder for Injection (GBP/US$), June’2022
Figure 9-123: Empliciti – Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
Figure 9-124: Empliciti – Cost of Single Cycle during Initial 2 Cycles & Subsequent Cycles (US$), June’2022
Figure 9-125: Vectibix - FDA Approval by Therapy Type
Figure 9-126: Vectibix - FDA Approval & Patent Expiration Year
Figure 9-127: Vectibix – Price for a Supply of 5 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-128: Vectibix – Price for a Supply of 20 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-129: UK – Cost of 20ml, 50ml & Per Unit Cost of Vectibix Solution (GBP/US$), June’2022
Figure 9-130: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), June’2022
Figure 9-131: Avastin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-132: Avastin – Sales Value by Region (%), Q1’2022
Figure 9-133: Global - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-134: US - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-135: Europe - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-136: Japan - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-137: ROW - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-138: Avastin - Sales Value by Region (US$/CHF Million), 2021
Figure 9-139: Avastin - Sales Value by Region (%), 2021
Figure 9-140: Global - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-141: US - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-142: Mvasi – Sales Value by Region (US$ Million), Q1’2022
Figure 9-143: Mvasi – Sales Value by Region (%), Q1’2022
Figure 9-144: Global - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-145: US - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-146: ROW - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-147: Mvasi – Sales Value by Region (US$ Million), 2021
Figure 9-148: Mvasi – Sales Value by Region (%), 2021
Figure 9-149: Global – Mvasi Quarterly Sales (US$ Million), 2021
Figure 9-150: US – Mvasi Quarterly Sales (US$ Million), 2021
Figure 9-151: Global - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 9-152: Zirabev – Sales Value by Region (US$ Million), Q1’2022
Figure 9-153: Zirabev – Sales Value by Region (%), Q1’2022
Figure 9-154: Global – Zirabev Sales (US$ Million), 2020 & 2021
Figure 9-155: US – Zirabev Sales (US$ Million), 2020 & 2021
Figure 9-156: Zirabev – Sales Value by Region (US$ Million), 2021
Figure 9-157: Zirabev – Sales Value by Region (%), 2021
Figure 9-158: Global – Zirabev Quarterly Sales (US$ Million), 2021
Figure 9-159: US – Zirabev Quarterly Sales (US$ Million), 2021
Figure 9-160: US – Zirabev Quarterly Sales (US$ Million), 2020
Figure 9-161: Gazyva – Value by Region (US$/CHF Million), Q1’2022
Figure 9-162: Global - Gazyva Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-163: US - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-164: Europe - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-165: Japan - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-166: ROW - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-167: Gazyva - Sales Value by Region (US$/CHF Million), 2021
Figure 9-168: Gazyva - Sales Value by Region (%), 2021
Figure 9-169: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 9-170: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 9-171: Phesgo – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-172: Phesgo – Sales Value by Region (%), Q1’2022
Figure 9-173: Global - Phesgo Sales Value (US$/CHF Million), 2020 & 2021
Figure 9-174: Phesgo - Sales Value by Region (US$/CHF Million), 2021
Figure 9-175: Phesgo - Sales Value by Region (%), 2021
Figure 9-176: Global - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-177: US - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-178: Europe - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-179: Herceptin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-180: Herceptin – Sales Value by Region (%), Q1’2022
Figure 9-181: Global - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-182: US - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-183: Europe - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-184: Japan - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-185: ROW - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-186: Herceptin - Sales Value by Region (US$/CHF Million), 2021
Figure 9-187: Herceptin - Sales Value by Region (%), 2021
Figure 9-188: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-189: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-190: Sarclisa - Sales Value by Region (US$/Euro Million), Q1’2022
Figure 9-191: Sarclisa - Sales Value by Region (%), Q1’2022
Figure 9-192: Global - Sarclisa Sales Value (US$/EUR Million), 2020 & 2021
Figure 9-193: US - Sarclisa Sales Value (US$/EUR Million), 2020 & 2021
Figure 9-194: Sarclisa - Sales Value by Region (US$/Euro Million), 2021
Figure 9-195: Sarclisa - Sales Value by Region (%), 2021
Figure 9-196: Sarclisa - Sales Value by Region (US$/Euro Million), 2020
Figure 9-197: Sarclisa - Sales Value by Region (%), 2020
Figure 9-198: Sarclisa – Sales Quarterly Value by Region (US$/Euro Million), 2021
Figure 9-199: US – Sales Quarterly Value by Region (US$/Euro Million), 2021
Figure 9-200: US - Monjuvi Sales Value (US$ Million), Q1’2021 & Q1’2022
Figure 9-201: US - Monjuvi Sales Value (US$ Million), 2020 & 2021
Figure 9-202: US - Monjuvi Quarterly Sales Value (US$ Million), 2021
Figure 9-203: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 & Q4’2020
Figure 9-204: Rituxan – Value by Region (US$/CHF Million), Q1’2022
Figure 9-205: Global - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-206: US - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-207: Europe - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-208: Japan - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-209: ROW - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-210: Rituxan - Sales Value by Region (US$/CHF Million), 2021
Figure 9-211: Rituxan - Sales Value by Region (%), 2021
Figure 9-212: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 9-213: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 9-214: Global - Empliciti Sales Value by Region (US$ Million), Q1’2022
Figure 9-215: Global - Empliciti Sales Value by Region (%), Q1’2022
Figure 9-216: Global - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 9-217: US - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 9-218: Global - Empliciti Sales Value by Region (US$ Million), 2021
Figure 9-219: Global - Empliciti Sales Value by Region (%), 2021
Figure 9-220: Global - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 9-221: US - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 9-222: Global - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 9-223: US - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 9-224: Global - Vectibix Sales Value by Region (US$ Million), Q1’2022
Figure 9-225: Global - Vectibix Sales Value by Region (%), Q1’2022
Figure 9-226: Global – Vectibix Sales (US$ Million), 2019 - 2021
Figure 9-227: US – Vectibix Sales (US$ Million), 2019 - 2021
Figure 9-228: Global - Vectibix Sales Value by Region (US$ Million), 2021
Figure 9-229: Global - Vectibix Sales Value by Region (%), 2021
Figure 9-230: Global – Vectibix Quarterly Sales (US$ Million), 2021
Figure 9-231: US – Vectibix Quarterly Sales (US$ Million), 2021
Figure 9-232: Global - Vectibix Quarterly Sales Value (US$ Million), 2020
Figure 9-233: US - Vectibix Quarterly Sales Value (US$ Million), 2020
Figure 9-234: Global - Kanjinti Sales Value by Region (US$ Million), Q1’2022
Figure 9-235: Global - Kanjinti Sales Value by Region (%), Q1’2022
Figure 9-236: Global – Kanjinti Sales Value (US$ Million), 2019 - 2021
Figure 9-237: US – Kanjinti Sales Value (US$ Million), 2019 - 2021
Figure 9-238: Kanjinti - Sales by Region (US$ Million), 2021
Figure 9-239: Kanjinti - Sales Value by Region (%), 2021
Figure 9-240: Global – Kanjinti Quarterly Sales (US$ Million), 2021
Figure 9-241: US – Kanjinti Quarterly Sales (US$ Million), 2021
Figure 9-242: Global – Kanjinti Quarterly Sales (US$ Million), 2020
Figure 9-243: US – Kanjinti Quarterly Sales (US$ Million), 2020
Figure 10-1: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Company, 2022 till 2028
Figure 10-2: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Country, 2022 till 2028
Figure 10-3: Global - Number of Combination Cancer Immunotherapies Clinical Trials by Disease Stage, 2022 till 2028
Figure 10-4: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Phase, 2022 till 2028
Figure 1-1: Currently Available Immunotherapeutic Approaches
Figure 1-2: Basis of Combination Immunotherapy
Figure 4-1: Global – Combination Cancer Immunotherapy Market Size (US$ Billion), 2020 & 2021
Figure 4-2: Global – Cancer Combination Immunotherapy Market by Indication (US$ Million), 2021
Figure 4-3: Global – Cancer Combination Immunotherapy Market by Indication (%), 2021
Figure 4-4: Global – Cancer Combination Immunotherapy Market by Region (US$ Million), 2021
Figure 4-5: Global – Cancer Combination Immunotherapy Market by Region (%), 2021
Figure 4-6: Global – Combination Cancer Immunotherapy Market Size (US$ Billion), 2022 - 2028
Figure 5-1: Global – Breast Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 5-2: Global – Breast Combination Cancer Immunotherapy Market Size (US$ Billion), 2020 & 2021
Figure 5-3: Global – Breast Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-4: Global – Kidney Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-5: Global – Kidney Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-6: Global – Lung Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-7: Global – Lung Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-8: Global – Liver Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-9: Global – Liver Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-10: Global – Gastric Combination Cancer Immunotherapy Market Size (US$ Million), 2021 - 2028
Figure 5-11: Global – Lymphoma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-12: Global – Lymphoma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-13: Global – Prostate Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-14: Global – Melanoma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-15: Global – Melanoma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-16: Global – Colorectal Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-17: Global – Colorectal Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-18: Global – Leukemia Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-19: Global – Leukemia Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-20: Global – Cervical Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-21: Global – Cervical Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-22: Global – Pancreatic Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-23: Global – Pancreatic Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-24: Global – Ovarian Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-25: Global – Ovarian Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-26: Global – Head & Neck Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-27: Global – Head & Neck Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 5-28: Global – Multiple Myeloma Combination Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 5-29: Global – Multiple Myeloma Combination Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-1: US – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-2: US vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-3: US – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-4: Europe – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-5: Europe vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-6: Europe vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-7: Europe – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-8: China – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-9: China vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-10: China vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-11: China – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-12: Japan – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-13: Japan vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-14: Japan vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-15: Japan – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-16: Australia – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-17: Australia vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-18: Australia vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-19: Australia – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-20: South Korea – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-21: South Korea – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-22: Canada – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-23: Canada vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-24: Canada vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-25: Canada – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 6-26: UK – Combination Cancer Immunotherapy Market Size (US$ Million), 2020 & 2021
Figure 6-27: UK vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-28: UK vs. ROW – Combination Cancer Immunotherapy Market Size (US$ Million), 2021
Figure 6-29: UK – Combination Cancer Immunotherapy Market Size (US$ Million), 2022 - 2028
Figure 7-1: Keytruda – Approval Year by Region
Figure 7-2: Keytruda Combination – FDA Approval Year by Indication
Figure 7-3: Keytruda Combination – EMA Approval Year by Indication
Figure 7-4: Keytruda – Patent Expiration Year by Region
Figure 7-5: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), June’2022
Figure 7-6: UK - Price for 4ml & Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), June’2022
Figure 7-7: Keytruda – Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks),
Figure 7-8: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), June’2022
Figure 7-9: Opdivo – Approval Year by Region
Figure 7-10: Opdivo Combination – FDA Approval by Indication
Figure 7-11: Opdivo - Patent Expiration Year by Region
Figure 7-12: US - Price for 4ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-13: US - Price for 10 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-14: US - Price for 12 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-15: US - Price for 24 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), June’2022
Figure 7-16: UK - Price for 4 ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-17: UK - Price for 10ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-18: UK - Price for 24ml Supply & Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), June’2022
Figure 7-19: Opdivo Combination Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June’2022
Figure 7-20: Yervoy Combination – FDA Approval Year by Region
Figure 7-21: Yervoy – Approval Year by Region
Figure 7-22: Yervoy – US & Europe Exclusivity Expiration Year
Figure 7-23: US - Price for 10ml Supply & Price Per ml of Yervoy 5mg/ml Intravenous Injection (US$), June’2022
Figure 7-24: US – Price for 40ml Supply & Price Per ml 5mg/ml Yervoy Intravenous Injection (US$), June’2022
Figure 7-25: UK - Price for 10ml & Price Per ml of Yervoy 50mg Intravenous Injection (GBP/US$), June’2022
Figure 7-26: UK - Price for 40ml & Price Per ml of Yervoy 200mg Intravenous Injection (GBP/US$), June’2022
Figure 7-27: Yervoy - Single Treatment Cycle & Full Treatment Average Cost for NSCLC (US$), June’2022
Figure 7-28: Yervoy & Opdivo Combination - Single Treatment Cycle & Full Treatment Average Cost for NSCLC (US$), June’2022
Figure 7-29: Imfinzi – Approval Year by Region
Figure 7-30: Imfinzi – FDA Approval & Patent Expiration Year
Figure 7-31: US– Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (US$), June’2022
Figure 7-32: US – Price for a Supply of 10 ml & Price Per ml of Imfinzi Solution for Injection (US$), June’2022
Figure 7-33: UK– Price for a Supply of 2.4ml & Price Per ml of Imfinzi Solution for Injection (GBP/US$), June’2022
Figure 7-34: UK– Price for a Supply of 10ml & Price Per ml of Imfinzi Solution for Injection (GBP/US$), June’2022
Figure 7-35: Imfinzi Combination Therapy - Single Treatment Cycle & Full Treatment Average Cost (US$), June’2022
Figure 7-36: Tecentriq – Approval Year by Region
Figure 7-37: Tecentriq Combination – FDA Approval Year by Indication
Figure 7-38: US- Price for 14ml Supply & Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), June’2022
Figure 7-39: US - Price for 20ml Supply & Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), June’2022
Figure 7-40: UK– Price for a Supply of 20ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), June’2022
Figure 7-41: UK– Price for a Supply of 14ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), June’2022
Figure 7-42: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), June’2022
Figure 7-43: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), June’2022
Figure 7-44: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), June’2022
Figure 7-45: Tuoyi – NMPA Approval by Indication
Figure 7-46: China– Price for a Supply of 2ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-47: China– Price for a Supply of 2.5ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-48: China– Price for a Supply of 6ml & Price Per ml of Tuoyi Solution for Injection (Yuan/US$), June’2022
Figure 7-49: Tislelizumab – NMPA Approval by Indication
Figure 7-50: US – Opdualag FDA Orphan Designation & Approval Year
Figure 7-51: US - Price for 20ml Supply & Price Per ml of Opdualag Intravenous Injection (US$), June’2022
Figure 7-52: Global - Keytruda Sales (US$ Million), Q1’2021 & Q1’2022
Figure 7-53: Global - Keytruda Sales Value (US$ Billion), 2018 - 2021
Figure 7-54: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 7-55: Global – Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 7-56: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022
Figure 7-57: Global - Opdivo Sales Value by Region (%), Q1’2022
Figure 7-58: Global - Opdivo Sales Value (US$ Million), 2018 - 2021
Figure 7-59: US - Opdivo Sales Value (US$ Million), 2018 - 2021
Figure 7-60: Global – Opdivo Sales Value by Region (US$ Million), 2021
Figure 7-61: Global - Opdivo Sales Value by Region (%), 2021
Figure 7-62: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-63: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-64: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-65: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-66: Global - Yervoy Sales Value by Region (US$ Million), Q1’2022
Figure 7-67: Global – Yervoy Sales Value by Region (%), Q1’2022
Figure 7-68: Global - Yervoy Sales Value (US$ Million), 2018 - 2021
Figure 7-69: US - Yervoy Sales Value (US$ Million), 2018 - 2021
Figure 7-70: Yervoy - Sales Value by Region (US$ Million), 2021
Figure 7-71: Yervoy - Sales Value by Region (US$ Million), 2021
Figure 7-72: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-73: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-74: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-75: US - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-76: Imfinzi – Sales Value by Region (US$ Million), Q1’2022
Figure 7-77: Imfinzi – Sales Value by Region (US$ Million), Q1’2022
Figure 7-78: Global - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-79: US - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-80: Europe - Imfinzi Sales Value (US$ Million), 2019 - 2021
Figure 7-81: Imfinzi - Sales Value by Region (US$ Million), 2021
Figure 7-82: Imfinzi - Sales Value by Region (%), 2021
Figure 7-83: Global - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 7-84: US - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 7-85: Global - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 7-86: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 7-87: Tecentriq – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 7-88: Tecentriq – Sales Value by Region (%), Q1’2022
Figure 7-89: Global - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-90: US - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-91: Europe - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-92: Japan - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-93: ROW - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-94: Tecentriq - Sales Value by Region (US$/CHF Million), 2021
Figure 7-95: Tecentriq - Sales Value by Region (%), 2021
Figure 7-96: Global - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-97: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021
Figure 7-98: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-1: Adcetris Combination - Approval Year by Region
Figure 8-2: Adcetris Combination - Approval Year in Hodgkin Lymphoma by Region
Figure 8-3: Adcetris Combination - Approval Year in Large Cell Lymphoma by Region
Figure 8-4: Adcetris - Patent Expiration by Region
Figure 8-5: UK - Cost of Supply of Adcetris 50mg Intravenous Powder (GBP/US$), June’2022
Figure 8-6: Adcetris - Cost of Supply of Vial for Injection by Region (US$), June’2022
Figure 8-7: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (Weeks)
Figure 8-8: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Stage III and IV Classical Hodgkin Lymphoma (US$), June’2022
Figure 8-9: Adcetris – Duration of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (Weeks)
Figure 8-10: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Classical Hodgkin Lymphoma (US$), June’2022
Figure 8-11: Adcetris – Maximum Cost of Single Treatment Cycle & Full Treatment of Previously Untreated Systemic ALCL or Other CD30 T-Cell Lymphomas (US$), June’2022
Figure 8-12: Polivy Combination - Approval Year by Region
Figure 8-13: US - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (US$), June’2022
Figure 8-14: UK - Price for Single Unit of Polivy 30mg & 140mg Intravenous Powder for Injection (GBP/US$), June’2022
Figure 8-15: Polivy - Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 8-16: Polivy – Cost of Single Dose, Single Treatment Cycle & Full Treatment of DLBCL (US$), June’2022
Figure 8-17: Global - Adcetris Sales (US$ Million), Q1’2021 & Q1’2022
Figure 8-18: Global - Adcetris Sales Value (US$ Million), 2018 - 2021
Figure 8-19: Global - Adcetris Quarterly Sales (US$ Million), 2021
Figure 8-20: Global - Adcetris Quarterly Sales (US$ Million), 2020
Figure 8-21: Polivy – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-22: Polivy – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 8-23: Global - Polivy Sales Value (US$/CHF Million), 2019 - 2021
Figure 8-24: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-25: US - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-26: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-27: Japan - Polivy Quarterly Sales Value (US$/CHF Million), Q2-Q4’2021
Figure 8-28: ROW - Polivy Quarterly Sales Value (US$/CHF Million), 2021
Figure 8-29: Polivy - Sales Value by Region (US$/CHF Million), 2021
Figure 8-30: Polivy - Quarterly Sales Value by Region (%), 2021
Figure 8-31: Global - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-32: US - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-33: Europe - Polivy Quarterly Sales Value (US$/CHF Million), 2020
Figure 8-34: Polivy - Annual Sales Value by Region (US$/CHF Million), 2020
Figure 8-35: Polivy - Sales Value by Region (%), 2020
Figure 8-36: Polivy – Quarterly Sales Value (US$/CHF Million), Q2-Q4'2019
Figure 9-1: Avastin – Approval Year by Region
Figure 9-2: Avastin Combination – FDA Approval Year by Indication
Figure 9-3: US– Price for a Supply of 10 & Price for Single 4ml Avastin Solution for Injection (US$), June’2022
Figure 9-4: US – Price for a Supply of 10 & Price for Single 16ml Avastin Solution for Injection (US$), June’2022
Figure 9-5: UK– Price for a Supply of 4ml & Price Per ml of Avastin Solution for Injection (GBP/US$), June’2022
Figure 9-6: UK– Price for a Supply of 16ml & Price Per ml of Avastin Solution for Injection (GBP/US$), June’2022
Figure 9-7: Avastin – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Cervical Cancer (US$), June’2022
Figure 9-8: Avastin – Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combination & Monotherapy (Weeks)
Figure 9-9: Mvasi – Approval Year by Region
Figure 9-10: Mvasi - Price for 4ml Supply & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-11: Mvasi - Price for 16 ml Supply & Price Per Unit of Intravenous Solution (US$), June’2022
Figure 9-12: Mvasi – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), June’2022
Figure 9-13: US– Price for a Supply of 4ml & Price Per ml of Zirabev Solution for Injection (US$), June’2022
Figure 9-14: US– Price for a Supply of 16ml & Price Per ml of Zirabev Solution for Injection (US$), June’2022
Figure 9-15: UK– Price for a Supply of 16ml, 4ml & Price Per ml of Zirabev Solution for Injection (GBP/US$), June’2022
Figure 9-16: Zirabev – Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC (US$), June’2022
Figure 9-17: UK– Price for a Supply of 4ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), June’2022
Figure 9-18: UK– Price for a Supply of 16ml & Price Per ml of Aybintio Solution for Injection (GBP/US$), June’2022
Figure 9-19: Arzerra – FDA Approval Year by Therapy
Figure 9-20: Arzerra – Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), June’2022
Figure 9-21: Arzerra – Price for a Supply of 50 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-22: Arzerra – Initial & Maintenance Dose for Relapsed CLL (mg)
Figure 9-23: Arzerra – Minimum & Maximum Treatment Cost for Relapsed CLL (US$), June’2022
Figure 9-24: Arzerra – Initial & Maintenance Dose for Refractory CLL (mg)
Figure 9-25: Arzerra – Treatment Duration for Refractory CLL (Weeks)
Figure 9-26: Arzerra – Minimum & Maximum Treatment Cost for Refractory CLL (US$), June’2022
Figure 9-27: Gazyva – FDA Approval Year by Therapy
Figure 9-28: US – Price for 40ml Supply & Price Per ml of Gazyva Intravenous Solution (US$), June’2022
Figure 9-29: Gazyva – Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)
Figure 9-30: Gazyva – Duration of Single Treatment Cycle & Full Treatment of CLL (Week)
Figure 9-31: Gazyva – Cost of Initial & Subsequent Treatment Cycle & Full Treatment Cost of CLL (US$), June’2022
Figure 9-32: US– Price for 5ml & Price Per ml of Herceptin Hylecta Subcutaneous Solution for Injection (US$), June’2022
Figure 9-33: Herceptin Hylecta – Duration of Single Treatment Cycle & Full Treatment (week)
Figure 9-34: Herceptin Hylecta – Cost of Single Treatment Cycle & Full Treatment (US$), June’2022
Figure 9-35: US– Price for various Supplies of Phesgo Subcutaneous Solution for Injection (US$), June’2022
Figure 9-36: UK– Price for a Supply of 16ml & 10ml of Phesgo Solution for Injection (GBP/US$), June’2022
Figure 9-37: Phesgo – Duration of Treatment by Type (Cycles)
Figure 9-38: Sarclisa – FDA Approval by Type
Figure 9-39: Sarclisa – FDA Approval & Patent Expiration Year
Figure 9-40: US – Price for 5 ml Supply & Price Per ml of Sarclisa 20mg/ml Intravenous Solution (US$), June’2022
Figure 9-41: US– Price for 25 ml Supply & Price Per ml of 20mg/ml Sarclisa Intravenous Solution (US$), June’2022
Figure 9-42: UK– Price for a Supply of 25ml & 5ml of Phesgo Solution for Injection (GBP/US$), June’2022
Figure 9-43: Sarclisa – Number of Dose Required in Initial & Subsequent Treatment Cycles (Weeks)
Figure 9-44: Herceptin Combination – FDA Approval Year by Cancer Type
Figure 9-45: Herceptin –Approval Year by Region
Figure 9-46: US– Price for a Supply of 10 & Price for Single Herceptin 150mg Powder for Injection (US$), June’2022
Figure 9-47: UK– Price for Single Herceptin 150mg Powder for Injection (GBP/US$), June’2022
Figure 9-48: Herceptin Combination – Initial & Maintenance Dose for Breast Cancer, Gastric & Esophageal Carcinoma (mg/kg)
Figure 9-49: Ogivri –Approval Year by Region
Figure 9-50: Ogivri – Price for 150mg & 420mg Powder for Injection (US$), June’2022
Figure 9-51: Ogivri – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-52: Ogivri – Average Cost of Initial Week, Maintenance Week & Annual (US$), June’2022
Figure 9-53: Herzuma –Approval Year by Region
Figure 9-54: US– Price for 150mg & 420mg Herzuma Powder for Injection (US$), June’2022
Figure 9-55: UK– Price for 150mg & 420mg Herzuma Powder for Injection (GBP/US$), June’2022
Figure 9-56: Herzuma – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-57: Herzuma – Average Cost of Initial Week, Maintenance Week & Annual (US$), June’2022
Figure 9-58: Trazimera –Approval Year by Region
Figure 9-59: US– Price for 150mg & 420mg Trazimera Powder for Injection (US$), June’2022
Figure 9-60: UK– Price for 150mg & 420mg Trazimera Powder for Injection (GBP/US$), June’2022
Figure 9-61: Trazimera – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-62: Trazimera – Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), June’2022
Figure 9-63: Kanjinti –Approval Year by Region
Figure 9-64: US – Price for 150mg & 420mg Powder for Injection (US$), June’2022
Figure 9-65: UK– Price for 150mg & 420mg Kanjinti Powder for Injection (GBP/US$), June’2022
Figure 9-66: Kanjinti – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-67: Kanjinti – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), June’2022
Figure 9-68: UK– Price for Single Zercepac 150mg Powder for Injection (GBP/US$), June’2022
Figure 9-69: Zercepac – Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
Figure 9-70: Zercepac – Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), June’2022
Figure 9-71: Darzalex Faspro – FDA Approval & Patent Expiration Year
Figure 9-72: US – Price for 15 ml Supply & Price Per ml of Darzalex Faspro Subcutaneous Solution (US$), June’2022
Figure 9-73: Darzalex Faspro – Duration of Dose Interval by Treatment Phase (Weeks)
Figure 9-74: Tafasitamab Combination – Approval Year by Region
Figure 9-75: Monjuvi – Number of Dose per Treatment Cycle by Phase
Figure 9-76: Monjuvi – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 9-77: Monjuvi – Cost of Single Dose, Single Treatment Cycle & Full Treatment (US$), June’2022
Figure 9-78: Rituxan Combination – FDA Approval Year by Indication
Figure 9-79: MabThera – Approval Year by Region
Figure 9-80: US– Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (US$), June’2022
Figure 9-81: US – Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (US$), June’2022
Figure 9-82: US – Price for a Supply of 100 ml & Price Per ml of Solution Rituxan for Injection (US$), June’2022
Figure 9-83: UK - Price for a Supply of 10 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), June’2022
Figure 9-84: UK - Price for a Supply of 50 ml & Price Per ml of Rituxan Solution for Injection (GBP/US$), June’2022
Figure 9-85: Rituxan Combination – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022
Figure 9-86: Rituxan Combination – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June’2022
Figure 9-87: Truxima – Price for a Supply of 10 ml & Price Per ml of Solution for Injection (US$), June’2022
Figure 9-88: Truxima – Price for a Supply of 50 ml & Price Per ml of Solution for Injection (US$), June’2022
Figure 9-89: UK – Cost of 50ml Truxima 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-90: UK – Cost of 2 Vials of Truxima 100mg/10ml Solution & Per Unit Cost of Vial (GBP/US$), June’2022
Figure 9-91: Truxima – Average Minimum & Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022
Figure 9-92: Truxima – Average Cost for Single Dose & Cost of Full Maintenance Phase for CLL (US$), June’2022
Figure 9-93: Riabni – Cost of Supply of 10ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-94: Riabni – Cost of Supply of 50ml & Per Unit Price of 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-95: Riabni – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), June’2022
Figure 9-96: Ruxience – Approval Year by Region
Figure 9-97: US – Cost of Supply of 10ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-98: US – Cost of Supply of 50ml & Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), June’2022
Figure 9-99: UK – Cost of 50ml Ruxience 500mg/50ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-100: UK – Cost of 10ml Ruxience 100mg/10ml Solution & Per Unit Cost of Solution (GBP/US$), June’2022
Figure 9-101: Ruxience – Cost of 8 Cycles, 4 Cycles & Single Cycle for Management of NHL (US$), June’2022
Figure 9-102: Rituxan Hycela – Price for 11.7 ml Supply & Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), June’2022
Figure 9-103: Rituxan Hycela – Price for 13.4 ml Supply & Price Per ml of 26,800 units–1,600 mg/13.4ml Subcutaneous Solution (US$), June’2022
Figure 9-104: Rituxan Hycela –Minimum & Maximum Duration of Follicular lymphoma Treatment (Weeks)
Figure 9-105: Rituxan Hycela – Average Minimum & Maximum Cost of Follicular lymphoma (US$), June’2022
Figure 9-106: Rituxan Hycela – Duration of Single Treatment Cycle & Full Treatment of Previously Untreated Follicular lymphoma (weeks)
Figure 9-107: Rituxan Hycela – Average Minimum & Maximum Cost of Previously Untreated Follicular lymphoma (US$), June’2022
Figure 9-108: Rituxan Hycela – Average Minimum & Maximum Cost of Diffuse Large B-Cell Lymphoma (US$), June’2022
Figure 9-109: Rituxan Hycela – Duration of CLL Treatment (Weeks)
Figure 9-110: Rituxan Hycela - Cost of Single Treatment Cycle & Full Treatment of CLL (US$), June’2022
Figure 9-111: Erbitux Combination - Approval Year by Cancer Type
Figure 9-112: US - Price for a Supply of 50 ml & Per unit Price of Erbitux Intravenous Solution (US$), June’2022
Figure 9-113: US - Price for a Supply of 100 ml & Per unit Price of Erbitux Intravenous Solution (US$), June’2022
Figure 9-114: UK – Cost of 100ml, 20ml & Per Unit Cost of Erbitux Solution (GBP/US$), June’2022
Figure 9-115: Cetuximab Combination – Initial & Maintenance Dose for Colorectal Cancer & Head and Neck Cancer (mg/ m2)
Figure 9-116: Cetuximab – Recommended Dose & Reduced Dose (mg/ m2)
Figure 9-117: Naxitamab – Cost of Supply of 10ml & Per Unit Cost of Intravenous Solution (US$), June’2022
Figure 9-118: Empliciti – FDA Approval by Therapy Type
Figure 9-119: Empliciti – Aooroval Year by Region
Figure 9-120: Empliciti – Patent Issue & Expiration Year
Figure 9-121: US – Price for 300mg & 400mg Supply of Empliciti Intravenous Powder for Injection (US$), June’2022
Figure 9-122: UK – Price for 300mg & 400mg Supply of Empliciti Intravenous Powder for Injection (GBP/US$), June’2022
Figure 9-123: Empliciti – Number of Dose Administration During Initial 2 Cycles & Subsequent Cycles
Figure 9-124: Empliciti – Cost of Single Cycle during Initial 2 Cycles & Subsequent Cycles (US$), June’2022
Figure 9-125: Vectibix - FDA Approval by Therapy Type
Figure 9-126: Vectibix - FDA Approval & Patent Expiration Year
Figure 9-127: Vectibix – Price for a Supply of 5 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-128: Vectibix – Price for a Supply of 20 ml & Price Per ml of Intravenous Solution (US$), June’2022
Figure 9-129: UK – Cost of 20ml, 50ml & Per Unit Cost of Vectibix Solution (GBP/US$), June’2022
Figure 9-130: Vectibix – Cost of Single Treatment Cycle & Annual Treatment Cost for Colorectal Cancer (US$), June’2022
Figure 9-131: Avastin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-132: Avastin – Sales Value by Region (%), Q1’2022
Figure 9-133: Global - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-134: US - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-135: Europe - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-136: Japan - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-137: ROW - Avastin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-138: Avastin - Sales Value by Region (US$/CHF Million), 2021
Figure 9-139: Avastin - Sales Value by Region (%), 2021
Figure 9-140: Global - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-141: US - Avastin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-142: Mvasi – Sales Value by Region (US$ Million), Q1’2022
Figure 9-143: Mvasi – Sales Value by Region (%), Q1’2022
Figure 9-144: Global - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-145: US - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-146: ROW - Mvasi Sales Value (US$ Million), 2019 - 2021
Figure 9-147: Mvasi – Sales Value by Region (US$ Million), 2021
Figure 9-148: Mvasi – Sales Value by Region (%), 2021
Figure 9-149: Global – Mvasi Quarterly Sales (US$ Million), 2021
Figure 9-150: US – Mvasi Quarterly Sales (US$ Million), 2021
Figure 9-151: Global - Mvasi Quarterly Sales Value (US$ Million), 2020
Figure 9-152: Zirabev – Sales Value by Region (US$ Million), Q1’2022
Figure 9-153: Zirabev – Sales Value by Region (%), Q1’2022
Figure 9-154: Global – Zirabev Sales (US$ Million), 2020 & 2021
Figure 9-155: US – Zirabev Sales (US$ Million), 2020 & 2021
Figure 9-156: Zirabev – Sales Value by Region (US$ Million), 2021
Figure 9-157: Zirabev – Sales Value by Region (%), 2021
Figure 9-158: Global – Zirabev Quarterly Sales (US$ Million), 2021
Figure 9-159: US – Zirabev Quarterly Sales (US$ Million), 2021
Figure 9-160: US – Zirabev Quarterly Sales (US$ Million), 2020
Figure 9-161: Gazyva – Value by Region (US$/CHF Million), Q1’2022
Figure 9-162: Global - Gazyva Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-163: US - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-164: Europe - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-165: Japan - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-166: ROW - Gazyva Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-167: Gazyva - Sales Value by Region (US$/CHF Million), 2021
Figure 9-168: Gazyva - Sales Value by Region (%), 2021
Figure 9-169: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 9-170: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 9-171: Phesgo – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-172: Phesgo – Sales Value by Region (%), Q1’2022
Figure 9-173: Global - Phesgo Sales Value (US$/CHF Million), 2020 & 2021
Figure 9-174: Phesgo - Sales Value by Region (US$/CHF Million), 2021
Figure 9-175: Phesgo - Sales Value by Region (%), 2021
Figure 9-176: Global - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-177: US - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-178: Europe - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-179: Herceptin – Sales Value by Region (US$/CHF Million), Q1’2022
Figure 9-180: Herceptin – Sales Value by Region (%), Q1’2022
Figure 9-181: Global - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-182: US - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-183: Europe - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-184: Japan - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-185: ROW - Herceptin Sales Value (US$/CHF Million), 2019 - 2021
Figure 9-186: Herceptin - Sales Value by Region (US$/CHF Million), 2021
Figure 9-187: Herceptin - Sales Value by Region (%), 2021
Figure 9-188: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-189: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
Figure 9-190: Sarclisa - Sales Value by Region (US$/Euro Million), Q1’2022
Figure 9-191: Sarclisa - Sales Value by Region (%), Q1’2022
Figure 9-192: Global - Sarclisa Sales Value (US$/EUR Million), 2020 & 2021
Figure 9-193: US - Sarclisa Sales Value (US$/EUR Million), 2020 & 2021
Figure 9-194: Sarclisa - Sales Value by Region (US$/Euro Million), 2021
Figure 9-195: Sarclisa - Sales Value by Region (%), 2021
Figure 9-196: Sarclisa - Sales Value by Region (US$/Euro Million), 2020
Figure 9-197: Sarclisa - Sales Value by Region (%), 2020
Figure 9-198: Sarclisa – Sales Quarterly Value by Region (US$/Euro Million), 2021
Figure 9-199: US – Sales Quarterly Value by Region (US$/Euro Million), 2021
Figure 9-200: US - Monjuvi Sales Value (US$ Million), Q1’2021 & Q1’2022
Figure 9-201: US - Monjuvi Sales Value (US$ Million), 2020 & 2021
Figure 9-202: US - Monjuvi Quarterly Sales Value (US$ Million), 2021
Figure 9-203: US - Monjuvi Quarterly Sales Value (US$ Million), Q3 & Q4’2020
Figure 9-204: Rituxan – Value by Region (US$/CHF Million), Q1’2022
Figure 9-205: Global - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-206: US - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-207: Europe - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-208: Japan - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-209: ROW - Rituxan Sales Value (US$/CHF Million), 2018 - 2021
Figure 9-210: Rituxan - Sales Value by Region (US$/CHF Million), 2021
Figure 9-211: Rituxan - Sales Value by Region (%), 2021
Figure 9-212: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 9-213: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 9-214: Global - Empliciti Sales Value by Region (US$ Million), Q1’2022
Figure 9-215: Global - Empliciti Sales Value by Region (%), Q1’2022
Figure 9-216: Global - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 9-217: US - Empliciti Sales Value (US$ Million), 2018 - 2020
Figure 9-218: Global - Empliciti Sales Value by Region (US$ Million), 2021
Figure 9-219: Global - Empliciti Sales Value by Region (%), 2021
Figure 9-220: Global - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 9-221: US - Empliciti Quarterly Sales Value (US$ Million), 2021
Figure 9-222: Global - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 9-223: US - Empliciti Quarterly Sales Value (US$ Million), 2020
Figure 9-224: Global - Vectibix Sales Value by Region (US$ Million), Q1’2022
Figure 9-225: Global - Vectibix Sales Value by Region (%), Q1’2022
Figure 9-226: Global – Vectibix Sales (US$ Million), 2019 - 2021
Figure 9-227: US – Vectibix Sales (US$ Million), 2019 - 2021
Figure 9-228: Global - Vectibix Sales Value by Region (US$ Million), 2021
Figure 9-229: Global - Vectibix Sales Value by Region (%), 2021
Figure 9-230: Global – Vectibix Quarterly Sales (US$ Million), 2021
Figure 9-231: US – Vectibix Quarterly Sales (US$ Million), 2021
Figure 9-232: Global - Vectibix Quarterly Sales Value (US$ Million), 2020
Figure 9-233: US - Vectibix Quarterly Sales Value (US$ Million), 2020
Figure 9-234: Global - Kanjinti Sales Value by Region (US$ Million), Q1’2022
Figure 9-235: Global - Kanjinti Sales Value by Region (%), Q1’2022
Figure 9-236: Global – Kanjinti Sales Value (US$ Million), 2019 - 2021
Figure 9-237: US – Kanjinti Sales Value (US$ Million), 2019 - 2021
Figure 9-238: Kanjinti - Sales by Region (US$ Million), 2021
Figure 9-239: Kanjinti - Sales Value by Region (%), 2021
Figure 9-240: Global – Kanjinti Quarterly Sales (US$ Million), 2021
Figure 9-241: US – Kanjinti Quarterly Sales (US$ Million), 2021
Figure 9-242: Global – Kanjinti Quarterly Sales (US$ Million), 2020
Figure 9-243: US – Kanjinti Quarterly Sales (US$ Million), 2020
Figure 10-1: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Company, 2022 till 2028
Figure 10-2: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Country, 2022 till 2028
Figure 10-3: Global - Number of Combination Cancer Immunotherapies Clinical Trials by Disease Stage, 2022 till 2028
Figure 10-4: Global - Number of Combination Cancer Immunotherapies in Clinical Trials by Phase, 2022 till 2028
LIST OF TABLES
Table 2-1: Advantages of Immunotherapy & their Combinations
Table 3-1: Global – Approval Combination Cancer Immunotherapy by Indication
Table 13-1: Ongoing Clinical Trial in Immune Checkpoint Inhibitor Combination Therapy
Table 13-2: ICI Combination Therapy with Chemotherapy in Preclinical Models
Table 13-3: Ongoing Clinical Trials in ICI Combined with Targeted Therapies
Table 14-1: Ongoing Clinical Trials in Monoclonal Antibody Combination Therapies
Table 14-2: Ongoing Clinical Trials in Bispecific Antibody Combination Therapies
Table 15-1: Ongoing Clinical Studies Evaluating Vaccines in Combination Therapy
Table 16-1: Ongoing Clinical Studies Evaluating Antibody Drug Conjugate in Combination Therapy
Table 17-1: Preclinical Studies Combining CAR T Cells with Oncolytic Virus
Table 17-2: Ongoing & Completed Clinical Trials Testing Combination Therapies with CAR T Cells
Table 18-1: Current Clinical Trials of Combination Therapy with OVs and Immune Checkpoint Inhibitors
Table 18-2: Mechanism of Synergy of Chemotherapy & Oncolytics Virus Combination
Table 2-1: Advantages of Immunotherapy & their Combinations
Table 3-1: Global – Approval Combination Cancer Immunotherapy by Indication
Table 13-1: Ongoing Clinical Trial in Immune Checkpoint Inhibitor Combination Therapy
Table 13-2: ICI Combination Therapy with Chemotherapy in Preclinical Models
Table 13-3: Ongoing Clinical Trials in ICI Combined with Targeted Therapies
Table 14-1: Ongoing Clinical Trials in Monoclonal Antibody Combination Therapies
Table 14-2: Ongoing Clinical Trials in Bispecific Antibody Combination Therapies
Table 15-1: Ongoing Clinical Studies Evaluating Vaccines in Combination Therapy
Table 16-1: Ongoing Clinical Studies Evaluating Antibody Drug Conjugate in Combination Therapy
Table 17-1: Preclinical Studies Combining CAR T Cells with Oncolytic Virus
Table 17-2: Ongoing & Completed Clinical Trials Testing Combination Therapies with CAR T Cells
Table 18-1: Current Clinical Trials of Combination Therapy with OVs and Immune Checkpoint Inhibitors
Table 18-2: Mechanism of Synergy of Chemotherapy & Oncolytics Virus Combination
